Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29541278 | 1.00 | TGFBR1 (0.53) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| SCHEMBL29358505 | 0.88 | TGFBR1 (0.70) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| SCHEMBL373524 | 0.88 | TGFBR1 (0.70) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| Water SCHEMBL29649719 | 0.87 | TGFBR1 (0.69) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| Water SCHEMBL21633982 | 0.87 | TGFBR1 (0.69) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| Water SCHEMBL29649721 | 0.87 | TGFBR1 (0.69) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| SCHEMBL29504108 | 0.81 | GAA (0.52) | TGFBR1MAPK14GABRA5ITGA5NTRK1 | |
| SCHEMBL30329533 | 0.80 | KDM4C (0.43) | TGFBR1SMN1; SMN2 | |
| Water SCHEMBL30838038 | 0.79 | TGFBR1 (0.53) | TGFBR1MAPK14GABRA5ITGA5LRRK2 | |
| SCHEMBL12444984 | 0.78 | TGFBR1 (0.57) | TGFBR1MAPK14ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118355110-A | Method for producing cartilage and bone | 默多克儿童研究所 | 2024-07-16 | — | — | CN | claimed |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | FATE THERAPEUTICS, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | FATE THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4647498-A2 | IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | Fate Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12419870-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12410403-B2 | Methods and compositions for inducing hematopoietic cell differentiation | FATE THERAPEUTICS, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-3805369-B1 | IMPROVED REPROGRAMMING METHODS AND CELL CULTURE PLATFORMS | FATE THERAPEUTICS INC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12385012-B2 | Methods and compositions for inducing hematopoietic cell differentiation | FATE THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2017127729-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. (US) | 2017-07-27 | — | — | WO | disclosed |
| US-20170081640-A1 | COMBINED CHEMICAL AND GENETIC APPROACHES FOR GENERATION OF INDUCED PLURIPOTENT STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE | 2017-03-23 | — | — | US | disclosed |
| US-9556417-B2 | Reprogramming of cells to a new fate | THE SCRIPPS RESEARCH INSTITUTE (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160264938-A1 | Reprogramming of Cells to a New Fate | THE SCRIPPS RESEARCH INSTITUTE | 2016-09-15 | — | — | US | disclosed |
| US-20120028351-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011159726-A2 | REPROGRAMMING OF CELLS TO A NEW FATE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | WO | disclosed |
| EP-2373784-A1 | GENERATION AND MAINTENANCE OF STEM CELLS | The Scripps Research Institute (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2011123572-A1 | REPROGRAMMING CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-10-06 | — | — | WO | disclosed |
| US-20110110899-A1 | Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells | SCRIPPS RESEARCH INSTITUTE (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011047300-A1 | INDUCTION OF PLURIPOTENT CELLS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110899-A1 | Combined Chemical and Genetic Approaches for Generation of Induced Pluripotent Stem Cells | POU2F2, POU2F1, RARB | TGFBR1 1893/4885MAPK14 2164/4885GABRA5 969/4885 |
| US-20260109951-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD4, CD22 | TGFBR1 443/4885MAPK14 1645/4885GABRA5 4171/4885 |
| US-12618049-B2 | Reprogramming methods and cell culture platforms | WNT3A, FGF2, MEF2D | TGFBR1 14/4885MAPK14 149/4885GABRA5 3169/4885 |
| US-20260062676-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | KIT, FLT1, HGF | TGFBR1 11/4885MAPK14 45/4885GABRA5 3254/4885 |
| US-20260035664-A1 | METHODS AND COMPOSITIONS FOR INDUCING HEMATOPOIETIC CELL DIFFERENTIATION | PBK, CD14, HGF | TGFBR1 94/4885MAPK14 1087/4885GABRA5 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.